Press Releases

Company press releases and official corporate announcements.

A centralized feed of corporate press releases, earnings announcements, mergers, and official statements. Content is presented for informational purposes and may require additional analysis for market relevance.

Articles

10,391 total articles

Diversified Energy TR-1

Diversified Energy TR-1

Barclays PLC has submitted a TR-1 notification regarding its holdings in Diversified Energy Company, indicating that its total voting rights have fallen below the notifiable threshold. The notification details changes in voting rights ownership and confirms that no major changes surpassing disclosure requirements have occurred.

Tencent Invests in Kaspi.kz Alongside Co-Founder & CEO Mikheil Lomtadze and Long-Term U.S. Institutional Investors

Tencent Invests in Kaspi.kz Alongside Co-Founder & CEO Mikheil Lomtadze and Long-Term U.S. Institutional Investors

Kaspi.kz, a leading fintech and super app operator in Kazakhstan and Türkiye, announced a strategic investment by Tencent, Kaspi.kz's Co-Founder and CEO Mikheil Lomtadze, senior management, and US institutional investors acquiring 6 million ADSs from existing shareholders, strengthening the company's capital base as it expands its market leadership…

Fiserv to Release First Quarter Earnings Results on May 5, 2026 and Confirms Details for May 14, 2026 Investor Day

Fiserv to Release First Quarter Earnings Results on May 5, 2026 and Confirms Details for May 14, 2026 Investor Day

Fiserv, Inc. will release its first quarter 2026 earnings results on May 5 before market open, followed by a webcast presentation. Furthermore, the company will hold an Investor Day on May 14 to detail its business strategy and medium-term outlook. Both events will be accessible via live webcast on the company's investor relations website.

Mountain Warehouse Launches Composable Ecommerce Store with BigCommerce to Accelerate Innovation and Global Growth

Mountain Warehouse Launches Composable Ecommerce Store with BigCommerce to Accelerate Innovation and Global Growth

Commerce's BigCommerce platform has powered Mountain Warehouse's launch of a new composable ecommerce store, replacing their decade-old system. This upgrade allows Mountain Warehouse to scale more efficiently, accelerate innovation, and improve global ecommerce operations, leveraging a flexible, modern tech stack with enhanced security and integrat…

Astec Names Chad Hartley Group President

Astec Names Chad Hartley Group President

Astec Industries, a Nasdaq-listed manufacturer specializing in equipment for road building and aggregate processing, announced the appointment of Chad Hartley as Group President of Infrastructure Solutions. Hartley brings extensive leadership experience from Regal Rexnord and Emerson Electric, and is expected to drive operational improvements and c…

Fulcrum Therapeutics to Host First Quarter 2026 Financial Results Conference Call and Webcast on Monday, April 27, 2026, at 8:00 a.m. ET

Fulcrum Therapeutics to Host First Quarter 2026 Financial Results Conference Call and Webcast on Monday, April 27, 2026, at 8:00 a.m. ET

Fulcrum Therapeutics, a clinical-stage biopharmaceutical company focused on rare hematological disorders, will release its Q1 2026 financial results on April 27, 2026, prior to market open. Management will hold a conference call and webcast at 8:00 a.m. ET to discuss the results and corporate updates, including progress on their lead program, pocir…

Amneal Announces Additional Positive Interim Phase 4 ELEVATE-PD Results with CREXONT® for Parkinson’s Disease, Including Over 3 More Hours of Daily “Good On” Time When Switching from RYTARY®

Amneal Announces Additional Positive Interim Phase 4 ELEVATE-PD Results with CREXONT® for Parkinson’s Disease, Including Over 3 More Hours of Daily “Good On” Time When Switching from RYTARY®

Amneal Pharmaceuticals announced encouraging interim data from its ongoing Phase 4 ELEVATE-PD study evaluating CREXONT®, an extended-release carbidopa/levodopa formulation for Parkinson's disease. Among 111 patients switching from existing therapies such as IR CD/LD and RYTARY®, CREXONT significantly increased daily 'Good On' time by approximately …

Phathom Pharmaceuticals to Report First Quarter 2026 Financial Results and Provide Business Update on Thursday, April 30, 2026

Phathom Pharmaceuticals to Report First Quarter 2026 Financial Results and Provide Business Update on Thursday, April 30, 2026

Phathom Pharmaceuticals announced it will report its Q1 2026 financial results and provide a business update via a live webcast on April 30, 2026. The company focuses on developing and commercializing novel gastrointestinal disease treatments, including its marketed product VOQUEZNA for GERD and H. pylori infection treatment in the U.S.

LENZ Therapeutics Announces Submission of Marketing Authorization Application to the Medicines and Healthcare products Regulatory Agency for VIZZ® for the Treatment of Presbyopia in the United Kingdom

LENZ Therapeutics Announces Submission of Marketing Authorization Application to the Medicines and Healthcare products Regulatory Agency for VIZZ® for the Treatment of Presbyopia in the United Kingdom

LENZ Therapeutics has submitted a Marketing Authorization Application to the UK's MHRA for VIZZ®, an FDA-approved aceclidine-based eye drop for presbyopia treatment. This marks the sixth regulatory submission outside the US as LENZ advances international commercialization efforts following positive Phase 3 trial results and early US market launch.

Beyond Cancer Reports Updated Survival and Safety Data from Phase 1 UNO Trial Presented at AACR 2026

Beyond Cancer Reports Updated Survival and Safety Data from Phase 1 UNO Trial Presented at AACR 2026

Beyond Air's subsidiary, Beyond Cancer, presented updated Phase 1 clinical data for its investigational immunotherapy UNO at AACR 2026, reporting prolonged survival in heavily pretreated cancer patients after a single intratumoral injection. The trial included patients with breast cancer, squamous cell carcinoma, and melanoma, many of whom had exha…

Allogene Therapeutics Showcases Momentum with Clinical and Platform Advancements in Allogeneic CAR T at AACR 2026

Allogene Therapeutics Showcases Momentum with Clinical and Platform Advancements in Allogeneic CAR T at AACR 2026

Allogene Therapeutics presented new scientific data and advancements at the AACR 2026 Annual Meeting, emphasizing the potential of their allogeneic CAR T cell therapies to provide off-the-shelf, scalable, and accessible treatment options for cancer and autoimmune diseases. The company showcased dual-targeting technology and expanded their pipeline,…

Super League Issues Letter Encouraging Shareholders to Vote in Support of the Misfits Ads Division Acquisition

Super League Issues Letter Encouraging Shareholders to Vote in Support of the Misfits Ads Division Acquisition

Super League Enterprise, Inc. announced a shareholder letter encouraging support for its acquisition of the Misfits Ads Division. The acquisition is expected to add profitable revenue, improve financial predictability, expand market share, and speed the company's path to sustainable cash-based EBITDA profitability. The transaction diversifies reven…

Immuneering Presents Genetic Data at AACR Annual Meeting Demonstrating Mechanism to Improve Durability and Survival, Supporting Use of Atebimetinib in First-Line Pancreatic Cancer and Beyond

Immuneering Presents Genetic Data at AACR Annual Meeting Demonstrating Mechanism to Improve Durability and Survival, Supporting Use of Atebimetinib in First-Line Pancreatic Cancer and Beyond

Immuneering Corporation presented new genetic data at the AACR Annual Meeting demonstrating that their MEK inhibitor, atebimetinib, rarely induces common resistance mutations in the MAPK pathway in treated patients. This supports the drug's potential for durable tumor shrinkage and improved survival in first-line pancreatic cancer. The company is a…

KBRA Affirms Ratings for Preferred Bank

KBRA Affirms Ratings for Preferred Bank

Kroll Bond Rating Agency (KBRA) has affirmed Preferred Bank's deposit and debt ratings with a stable outlook, highlighting the bank's robust profitability, high-yield loan portfolio, and efficient branch-light business model. The strong 2025 return on assets (ROA) of 1.84% underpins these ratings. Preferred Bank continues to serve a diverse custome…